Acadian Asset Management
AVTX icon

Acadian Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Acadian Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,471
Closed -$26K – 2023
2025
Q4 		$26K Buy
+1,471
New +$24.8K ﹤0.01% 1878
2023
Q4 		– Sell
-1,180
Closed -$34K – 1673
2023
Q3 		$34K Buy
+1,180
New +$52.7K ﹤0.01% 1466
2018
Q2 		– Sell
-19
Closed -$229K – 1698
2018
Q1 		$229K Sell
19
-2
-10% -$22.5K ﹤0.01% 1029
2017
Q4 		$194K Buy
+21
New +$90.4K ﹤0.01% 964

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Acadian Asset Management's AVTX Position: Q1 2026 in Review

Acadian Asset Management sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 1,471 shares — an estimated $26K sold.

Acadian Asset Management first reported a position in AVTX in Q4 2017 and held it in 4 quarters. The position peaked at $229K in Q1 2018. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Acadian Asset Management reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 1,471 Avalo Therapeutics shares in Q1 2026, an estimated $26K.
  • Acadian Asset Management first reported a position in Avalo Therapeutics in Q4 2017 and held it in 4 quarters.
  • Acadian Asset Management's Avalo Therapeutics position peaked at $229K in Q1 2018.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.